Literature DB >> 9496695

Cervical secretions in pregnant women colonized rectally with group B streptococci have high levels of antibodies to serotype III polysaccharide capsular antigen and protein R.

K Hordnes1, T Tynning, A I Kvam, L Bevanger, T A Brown, R Jonsson, B Haneberg.   

Abstract

Group B streptococci (GBS) colonizing the female genital tract will often infect newborn infants during delivery. In 200 pregnant women studied, 14% were colonized with GBS in the cervix, 12% in the rectum, and 9% in both cervix and rectum. We have previously reported that antibody levels to GBS serotypes Ia, II, and III in sera and cervical secretions were increased in women colonized in the rectum and/or cervix, when analyzed by a whole-cell ELISA. Here, we report the levels of antibodies to GBS serotype III capsular polysaccharide antigen (CPS III) and to protein antigen R4, which are present in most GBS III strains. Compared to culture-negative women, the group of women colonized rectally had markedly elevated levels of immunoglobulin (Ig)A and IgG antibodies in cervical secretions to both CPS III and protein R4 (P < 0.01 and P < 0.001, respectively). In sera, the corresponding differences between culture-negative and culture-positive women were less pronounced, or not present. In contrast to antibody levels to whole-cell GBS, antibody levels to CPS III and protein R4 in cervical secretions were not significantly increased in women colonized only in the cervix, except that IgA antibodies to protein R4 were slightly elevated (P < 0.05). These findings suggest that capsular type-specific polysaccharides and protein R4 in a mucosal vaccine might induce protective antibodies against GBS colonization of the uterine cervix.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496695     DOI: 10.1046/j.1365-3083.1998.00283.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Clonal variability of group B Streptococcus among different groups of carriers in southern Israel.

Authors:  D Marchaim; S Efrati; R Melamed; L Gortzak-Uzan; K Riesenberg; R Zaidenstein; F Schlaeffer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-07       Impact factor: 3.267

3.  Antibodies against Streptococcus agalactiae proteins c(alpha) and R4 in sera from pregnant women from Norway and Zimbabwe.

Authors:  S R Moyo; J A Maeland; J Mudzori
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization.

Authors:  Jacqueline A Baker; Emma L Lewis; Leah M Byland; Maryam Bonakdar; Tara M Randis; Adam J Ratner
Journal:  Vaccine       Date:  2017-02-02       Impact factor: 3.641

6.  Expression of group B protective surface protein (BPS) by invasive and colonizing isolates of group B streptococci.

Authors:  Aurea E Flores; G S Chhatwal; Sharon L Hillier; Carol J Baker; Patricia Ferrieri
Journal:  Curr Microbiol       Date:  2014-08-10       Impact factor: 2.188

7.  Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.

Authors:  Charlotte Larsson; Jan Holmgren; Gunnar Lindahl; Charlotta Bergquist
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.